Research programme: TRPA1 protein inhibitors - Ario Pharma

Drug Profile

Research programme: TRPA1 protein inhibitors - Ario Pharma

Latest Information Update: 27 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PharmEste
  • Developer Ario Pharma
  • Class Small molecules
  • Mechanism of Action TRPA1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Asthma

Most Recent Events

  • 11 Sep 2014 Research programme: TRPA1 protein inhibitors - Ario Pharma is available for licensing as of 11 Sep 2014. http://www.ariopharma.com/
  • 11 Sep 2014 Preclinical trials in Asthma in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top